Your browser doesn't support javascript.
loading
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
Moltó, José; Santos, José R; Pérez-Alvarez, Nuria; Cedeño, Samandhy; Miranda, Cristina; Khoo, Saye; Else, Laura; Llibre, Josep Maria; Valle, Marta; Clotet, Bonaventura.
Affiliation
  • Moltó J; Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Ctra de Canyet, Badalona, Barcelona, Spain. jmolto@flsida.org
Antimicrob Agents Chemother ; 52(11): 3928-32, 2008 Nov.
Article in En | MEDLINE | ID: mdl-18725446
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonamides / HIV Infections / HIV Protease Inhibitors Type of study: Observational_studies / Prognostic_studies Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2008 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonamides / HIV Infections / HIV Protease Inhibitors Type of study: Observational_studies / Prognostic_studies Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2008 Document type: Article Affiliation country: Country of publication: